MA66598A1 - Composition pharmaceutique comprenant un dérivé de phtalazinone pour coadministration avec un médicament anticancéreux - Google Patents

Composition pharmaceutique comprenant un dérivé de phtalazinone pour coadministration avec un médicament anticancéreux

Info

Publication number
MA66598A1
MA66598A1 MA66598A MA66598A MA66598A1 MA 66598 A1 MA66598 A1 MA 66598A1 MA 66598 A MA66598 A MA 66598A MA 66598 A MA66598 A MA 66598A MA 66598 A1 MA66598 A1 MA 66598A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
administration
anticancer drug
phthalazinone derivative
phthalazinone
Prior art date
Application number
MA66598A
Other languages
English (en)
French (fr)
Inventor
Yeongran YOO
Won Sik Lee
Kyoung Soo Ha
Eun-jihn ROH
Myongjae LEE
Minju HONG
Sungyeon CHOI
Jeong Eun Kim
In-gyu JE
Jong-Ha Lim
Original Assignee
Idience Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idience Co., Ltd filed Critical Idience Co., Ltd
Publication of MA66598A1 publication Critical patent/MA66598A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA66598A 2022-01-25 2023-01-25 Composition pharmaceutique comprenant un dérivé de phtalazinone pour coadministration avec un médicament anticancéreux MA66598A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263302834P 2022-01-25 2022-01-25
PCT/IB2023/000030 WO2023144626A1 (en) 2022-01-25 2023-01-25 Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug

Publications (1)

Publication Number Publication Date
MA66598A1 true MA66598A1 (fr) 2024-11-29

Family

ID=87470837

Family Applications (1)

Application Number Title Priority Date Filing Date
MA66598A MA66598A1 (fr) 2022-01-25 2023-01-25 Composition pharmaceutique comprenant un dérivé de phtalazinone pour coadministration avec un médicament anticancéreux

Country Status (14)

Country Link
US (1) US20250120970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469051A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505381A (cg-RX-API-DMAC7.html)
KR (1) KR20240138069A (cg-RX-API-DMAC7.html)
CN (1) CN118613264A (cg-RX-API-DMAC7.html)
AU (1) AU2023210923A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249330A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002218A1 (cg-RX-API-DMAC7.html)
IL (1) IL314334A (cg-RX-API-DMAC7.html)
JO (1) JOP20240162A1 (cg-RX-API-DMAC7.html)
MA (1) MA66598A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024009168A (cg-RX-API-DMAC7.html)
TW (1) TW202339753A (cg-RX-API-DMAC7.html)
WO (1) WO2023144626A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019426A1 (zh) * 2010-08-09 2012-02-16 上海恒瑞医药有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2015037939A1 (en) * 2013-09-13 2015-03-19 Ildong Pharm Co., Ltd. A novel phtalazinone derivatives and manufacturing process thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2833883A4 (en) * 2012-04-06 2015-12-23 Indus Pharmaceuticals Inc NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES
US12036222B2 (en) * 2018-04-04 2024-07-16 The Wistar Institut of Anatomy and Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor
WO2021214502A1 (en) * 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
KR102913343B1 (ko) * 2020-04-21 2026-01-15 아이디언스 주식회사 프탈라지논 화합물의 결정형

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019426A1 (zh) * 2010-08-09 2012-02-16 上海恒瑞医药有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2015037939A1 (en) * 2013-09-13 2015-03-19 Ildong Pharm Co., Ltd. A novel phtalazinone derivatives and manufacturing process thereof

Also Published As

Publication number Publication date
TW202339753A (zh) 2023-10-16
CA3249330A1 (en) 2023-08-03
MX2024009168A (es) 2024-08-09
JP2025505381A (ja) 2025-02-26
EP4469051A1 (en) 2024-12-04
KR20240138069A (ko) 2024-09-20
CN118613264A (zh) 2024-09-06
IL314334A (en) 2024-09-01
CL2024002218A1 (es) 2024-12-20
WO2023144626A1 (en) 2023-08-03
EP4469051A4 (en) 2025-12-17
AU2023210923A1 (en) 2024-07-25
US20250120970A1 (en) 2025-04-17
JOP20240162A1 (ar) 2024-07-23

Similar Documents

Publication Publication Date Title
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
MX2022003446A (es) Composiciones de vesiculas lipidicas con agentes potenciadores de la penetracion.
MA27154A1 (fr) Derives de quinazoline pour le traitement d'une croissance cellulaire anormale
MA61691A1 (fr) Administration orale de conjugues antisiens ciblant pcsk9
WO2003105800A3 (de) Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen
MA27710A1 (fr) Formulations pharmaceutiques liquides de palonosetrone
BRPI0508251A (pt) métodos para o tratamento de tinido auditivo induzido por excitotoxicidade coclear
MA34516B1 (fr) Imidizopyridazines substituees
CA2294783A1 (fr) Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA26965A1 (fr) Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
WO2001010387A3 (en) Antiviral therapy use of P-glycoprotein modulators
CO2021005221A2 (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
PT94832A (pt) Processo para a preparacao de derivados substituidos de aminoalcoxibenzeno e de composicoes farmaceuticas que os contem
CA3156022A1 (en) METHODS OF TREATING CANCER USING A COMBINATION OF A PLATINUM AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
MA45202A1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
FR3108504B1 (fr) Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement d’altérations de la fonction respiratoire lors d’une infection virale
JOP20250196A1 (ar) طرق تقليل خطر الأحداث القلبية الوعائية الضارة الكبرى لدى مرضى الوقاية الأولية
MX2024014063A (es) Metodos para tratar el sindrome de cushing y trastornos hepaticos, y para reducir la toxicidad hepatica de otros farmacos administrados a un paciente
BR112022026558A2 (pt) Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo
JOP20240162A1 (ar) تركيبة صيدلية تتضمن مشتق فثالازينون للإعطاء المشترك مع عقار مضاد للسرطان
FR2869539A1 (fr) Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
MX2007002941A (es) Composiciones de emulsion estables para administracion intravenosa que tienen eficacia libre de conservadores.
MA57759B2 (fr) Méthodes et compositions pour le traitement de l'hémangiome